Biohaven (NYSE:BHVN) Earns Overweight Rating from Cantor Fitzgerald

Cantor Fitzgerald reissued their overweight rating on shares of Biohaven (NYSE:BHVN) in a report published on Thursday, Benzinga reports.

A number of other analysts have also commented on the stock. TD Cowen upped their price objective on shares of Biohaven from $35.00 to $55.00 and gave the company an outperform rating in a research note on Friday, March 1st. UBS Group started coverage on shares of Biohaven in a research note on Tuesday, February 6th. They set a buy rating and a $59.00 price objective for the company. Royal Bank of Canada reaffirmed an outperform rating and set a $61.00 price objective on shares of Biohaven in a research note on Tuesday, April 9th. JPMorgan Chase & Co. upped their price objective on shares of Biohaven from $32.00 to $56.00 and gave the company an overweight rating in a research note on Friday, February 23rd. Finally, HC Wainwright upped their target price on Biohaven from $50.00 to $63.00 and gave the company a buy rating in a report on Monday, March 4th. Eight investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Biohaven currently has a consensus rating of Buy and a consensus price target of $52.00.

Biohaven Trading Down 4.2 %

Shares of NYSE BHVN opened at $42.16 on Thursday. Biohaven has a twelve month low of $12.35 and a twelve month high of $62.21. The company has a market capitalization of $3.44 billion, a price-to-earnings ratio of -7.45 and a beta of 1.18. The firm has a 50-day moving average of $52.03 and a two-hundred day moving average of $41.24.

Biohaven (NYSE:BHVN) last posted its quarterly earnings data on Thursday, February 29th. The company reported ($1.81) EPS for the quarter, missing analysts’ consensus estimates of ($1.41) by ($0.40). As a group, research analysts predict that Biohaven will post -5.85 earnings per share for the current year.

Hedge Funds Weigh In On Biohaven

A number of large investors have recently made changes to their positions in BHVN. US Bancorp DE increased its holdings in Biohaven by 19.1% in the first quarter. US Bancorp DE now owns 586 shares of the company’s stock worth $70,000 after buying an additional 94 shares during the last quarter. Cetera Advisor Networks LLC acquired a new position in Biohaven in the first quarter worth approximately $332,000. AlphaCrest Capital Management LLC acquired a new position in Biohaven in the first quarter worth approximately $344,000. BlackRock Inc. increased its holdings in Biohaven by 0.5% in the first quarter. BlackRock Inc. now owns 4,656,866 shares of the company’s stock worth $552,163,000 after buying an additional 21,586 shares during the last quarter. Finally, Dimensional Fund Advisors LP increased its holdings in Biohaven by 55.3% in the first quarter. Dimensional Fund Advisors LP now owns 82,599 shares of the company’s stock worth $9,794,000 after buying an additional 29,413 shares during the last quarter. Institutional investors and hedge funds own 88.78% of the company’s stock.

Biohaven Company Profile

Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities.